Project description:To discover the potential drivers of TNBC metastasis, we established an in vivo model by injecting MDA-MB-231cells into the tail veins of mice. Then, the breast tumor cells that successfully grew into metastatic lung tumors were collected and expanded in vitro, followed by re-injected into the tail veins of mice for lung metastasis. After three rounds of selection, a highly metastatic subline, MDA-MB-231-P3, was established, and more frequent micro-metastasis was detected in MDA-MB-231-P3 groups than that of MDA-MB-231 groups when the lungs of mice were stained with hematoxylin and eosin (HE). The lncRNA profiles of MDA-MB-231 or MDA-MB-231-P3 cells were analyzed by lncRNA sequencing. A total of 267 lncRNAs in MDA-MB-231-P3 cells were upregulated more than 2-fold in comparison to the MDA-MB-231 cells.
Project description:Aurora Kinase B and ZAK interaction model
Equivalent of the stochastic model used in "Network pharmacology model predicts combined Aurora B and ZAK inhibition in MDA-MB-231 breast cancer cells" by Tang et. al. 2018.
The only difference is cell division and partitioning of the components, which are available in the original model for SGNS2.
Project description:Dicer, RNase III endonuclease, is an essential enzyme in miRNA biogenesis that regulates target gene expression, and it has been reported that aberrant expressions of Dicer associate with the clinical outcomes of patients in various cancers. To explore the miRNA differencial expression regulated by Dicer in MDA-MB-231/E1A cells, the microarray profiling analysis was employed to conduct differentially expressed miRNAs in stable MDA-MB-231/vector, MDA-MB-231/E1A, and MDA-MB-231/E1A/shDicer cells.
Project description:To further study the regulation of TAF7 on cells, the transcriptome sequencing on MDA MB-231 cells, MDA MB-231/shTAF7 cells, MDA 231-LM2 and MDA 231-LM2/shTAF7 cells were performed.
Project description:We report the high-throughput profiling of histone modifications( H3K4me3 and H3K27ac) inTRIM11 knockdown and KDM5C knockdown MDA-MB-231 cells. we generated genome-wide chromatin-state maps of MDA-MB-231 cells.This study provides the localization of H3K4me3 and H3K27ac on chromatin in TRIM11 knockdown and KDM5C knockdown MDA-MB-231 cells.
Project description:This Series reports results of miRNA profiling of estrogen-receptor-positive (MCF7) and estrogen-receptor-negative (MDA-MB-231) cells. Retinoic Acid (RA) induces mir-21 in MCF-7 but not in MDA-MB-231 cells. MCF-7 and MDA-MB-231 cells were treated (or not) with retinoic acid (RA) and grown for either 6 hours or 48 hours.
Project description:K-GG ubiquitin profiling of DLD-1 and MDA-MB-231 cells treated with the selective USP9X inhibitor WEHI-092 at 10 µM for 30 min, 6 h, and 24 h (and DMSO-treated control). This dataset also includes DLD-1 cells treated with FT671 (USP7 inhibitor) at 10 µM for 30 min and 6 h.Sample IDs:#1-5 Control 30 min DLD-1#6-10 FT671 30 min DLD-1#11-15 WEHI-092 30 min DLD-1#16-20 Control 360 min DLD-1#21-25 FT671 360 min DLD-1#26-30 WEHI-092 360min DLD-1#31-35 Control 30 min MDA-MB-231#36-40 WEHI-092 30 min MDA-MB-231#41-45 Control 360 min MDA-MB-231#46-50 WEHI-092 360 min MDA-MB-231#51-55 Control 24 h MDA-MB-231#56-60 WEHI-092 24 h MDA-MB-231
Project description:Global proteomics dataset for K-GG ubiquitin profiling of DLD-1 and MDA-MB-231 cells treated with the selective USP9X inhibitor WEHI-092 at 10 µM for 30 min, 6 h, and 24 h (and DMSO-treated control). This dataset also includes DLD-1 cells treated with FT671 (USP7 inhibitor) at 10 µM for 30 min and 6 h. Sample IDs: #1-5 Control 30 min DLD-1 #6-10 FT671 30 min DLD-1 #11-15 WEHI-092 30 min DLD-1 #16-20 Control 360 min DLD-1 #21-25 FT671 360 min DLD-1 #26-30 WEHI-092 360min DLD-1 #31-35 Control 30 min MDA-MB-231 #36-40 WEHI-092 30 min MDA-MB-231 #41-45 Control 360 min MDA-MB-231 #46-50 WEHI-092 360 min MDA-MB-231 #51-55 Control 24 h MDA-MB-231 #56-60 WEHI-092 24 h MDA-MB-231
Project description:K-GG ubiquitin profiling of DLD-1 and MDA-MB-231 cells treated with the selective USP9X inhibitor WEHI-092 at 10 µM for 30 min, 6 h, and 24 h (and DMSO-treated control). This dataset also includes DLD-1 cells treated with FT671 (USP7 inhibitor) at 10 µM for 30 min and 6 h. Sample IDs: #1-5 Control 30 min DLD-1 #6-10 FT671 30 min DLD-1 #11-15 WEHI-092 30 min DLD-1 #16-20 Control 360 min DLD-1 #21-25 FT671 360 min DLD-1 #26-30 WEHI-092 360min DLD-1 #31-35 Control 30 min MDA-MB-231 #36-40 WEHI-092 30 min MDA-MB-231 #41-45 Control 360 min MDA-MB-231 #46-50 WEHI-092 360 min MDA-MB-231 #51-55 Control 24 h MDA-MB-231 #56-60 WEHI-092 24 h MDA-MB-231
